Top Markets
#1 Black Phoenix Black Phoenix +166.95%
#2 Islamic Coin Islamic Coin +158.16%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +46.33%
#5 Cryptopia Cryptopia +20.92%
#6 Test Test +19.84%
#7 Quantum Resistant Ledger Quantum Resistant Ledger +19.61%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.95%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +9.99%
#10 Useless Coin Useless Coin +8.99%
Coin of the day
Black Phoenix Black Phoenix
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Arno Therapeutics, Inc. Arno Therapeutics, Inc.

Arno Therapeutics, Inc.

ARNI
Peringkat dalam Saham #42094
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a... Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
Harga Saham
$0.0001
Terakhir disinkronkan: 2026-08-11
Kapitalisasi Pasar
$4.94K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Arno Therapeutics, Inc. (ARNI)

Kategori

Healthcare
Margin Operasi untuk Arno Therapeutics, Inc. (ARNI)
Margin Operasi per 2026 TTM: 0.00%
Menurut laporan keuangan dan harga saham terbaru dari Arno Therapeutics, Inc., margin operasi saat ini (TTM) adalah 0.00%. Pada akhir 2026, margin operasi perusahaan adalah 0.00%.
Riwayat margin operasi untuk Arno Therapeutics, Inc. dari 2026 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Margin Operasi untuk perusahaan sejenis atau pesaing
Perusahaan Margin Operasi Perbedaan Margin Operasi Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.